What is Cellecta?
Cellecta, Inc. operates as a specialized provider of genomic products and services, primarily focused on the complex requirements of drug target and biomarker discovery. The company offers a comprehensive suite of tools, including CRISPR and RNAi libraries, which are essential for researchers conducting functional screening and cell engineering. By integrating advanced bioinformatics analysis, Cellecta provides a holistic solution for clients aiming to identify and validate genes of interest for novel therapeutic applications.
The company's market position is defined by its commitment to customizable genomic analysis, which serves as a cornerstone for pharmaceutical and academic research institutions. Through its diverse portfolio, Cellecta enables the acceleration of drug development pipelines, effectively bridging the gap between raw genetic data and actionable therapeutic insights.
How much funding has Cellecta raised?
Cellecta has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Cellecta
PPP
Public-Private Partnership
What's next for Cellecta?
With the successful completion of this late-stage financing, Cellecta is well-positioned to expand its service capabilities and enhance its existing library offerings. The strategic allocation of this capital will likely focus on scaling bioinformatics infrastructure and deepening its footprint in the therapeutic discovery market. As the industry moves toward more complex gene-editing applications, Cellecta's focus on functional genomics will be pivotal in maintaining its competitive edge.
Looking ahead, the company is expected to prioritize the integration of new screening technologies and the expansion of its global service reach. By maintaining its focus on high-quality genomic data and customizable research support, Cellecta is poised to remain a key partner for organizations navigating the intricacies of modern drug discovery and biomarker identification.
